/=50%: The EMPOWER-Lung 1 study"." /> /=50%: The EMPOWER-Lung 1 study". Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165. " />

Read + Share

. Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study". Cancer 2024 Feb 23. doi: 10.1002/cncr.35165.
PMID: 38396349

• /=50%: The EMPOWER-Lung 1 study".&body=Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study". . Cancer 2024 Feb 23. doi: 10.1002/cncr.35165. https://m.amedeo.com/38396349 " ALT="Email" TITLE="Email">Email

• /=50%: The EMPOWER-Lung 1 study".&summary=. Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study". Cancer 2024 Feb 23. doi: 10.1002/cncr.35165.&source=https://m.amedeo.com" target="linkedin">LinkedIn

• Facebook

• Twitter

---

Privacy Policy